PTGX Protagonist Therapeutics, Inc.
$148.18▲ +2.08%
Healthcare
Other
After hours
$148.18▲ +0.00%
Sep 11, 7:30 PM ET
Volume 478.0K
Avg Volume (10D) 517.4K
Key Metrics & Fundamentals
Market Cap
$9.59B
P/E Ratio
143.9
Div Yield
–%
52W Range
57.90 - 160.81
% vs 50 MA
3.72%
% vs 200 MA
38.11%
RSI-14
53.4
MACD Histogram
-1.1000
Beta (1Y vs SPY)
0.17
Free Cash Flow
$218.88M
Gross Rev
$213.48M
Gross Profit
$213.48M
EBITDA
$159.16M
COGS
–
Operating Exp
$54.71M
Operating Income
$158.77M
EBIT
$158.77M
Pretax Income
$165.11M
Net Income
$162.85M
EPS (Diluted)
2.29
Price & Volume History
Loading chart…
Recent News
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
MT Newswires · Sep 11, 2026 7:23 AM
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire · Sep 8, 2026 8:05 PM
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey · Sep 6, 2026 12:55 PM
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Insider Monkey · Sep 4, 2026 4:14 PM
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
ACCESS Newswire · Sep 2, 2026 11:05 AM
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News
Simply Wall St. · Sep 1, 2026 11:07 PM
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
Simply Wall St. · Sep 1, 2026 12:14 PM
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
Simply Wall St. · Sep 1, 2026 8:13 AM
Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?
Simply Wall St. · Sep 1, 2026 5:05 AM
Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says
MT Newswires · Aug 31, 2026 6:53 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PTGX's money flow as a full page
Social Sentiment
No Reddit posts found for PTGX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.